Top ▲
Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
RAGE (advanced glycosylation end-product specific receptor)
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||
|
FcαRI (Fc alpha receptor / CD89)
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||
|
FcγRIIa (Fc gamma receptor IIa / CD32A) Show summary »« Hide summary
|
|||||||||||||||||||||||
|
FcγRIIb (Fc gamma receptor IIb / CD32B) Show summary »« Hide summary
|
|||||||||||||||||||||||
|
FcγRIIIa (Fc gamma receptor IIIa / CD16A)
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||
|
FcμRI (Fc mu receptor)
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||
|
CD155 (PVR cell adhesion molecule)
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||
|
TIGIT
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||
|
TREM1 (triggering receptor expressed on myeloid cells 1) Show summary »« Hide summary
|
|||||||||||||||||||||||
|
TREM2 (triggering receptor expressed on myeloid cells 2) Show summary »« Hide summary
|
1. Arts RJ, Joosten LA, Dinarello CA, Kullberg BJ, van der Meer JW, Netea MG. (2011) TREM-1 interaction with the LPS/TLR4 receptor complex. Eur Cytokine Netw, 22 (1): 11-4. [PMID:21393102]
2. Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, Diacovo TG, Cella M, Colonna M. (2009) A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol, 39 (3): 695-703. [PMID:19197944]
3. Bouchon A, Facchetti F, Weigand MA, Colonna M. (2001) TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature, 410 (6832): 1103-7. [PMID:11323674]
4. Brand V, Feuerbach D, Gasparini F, George N, Schaadt E, Shimshek D, Srinivas H, Waldhuber M, Wilken R. (2022) TREM2 stabilizing antibodies. Patent number: US11492402B2. Assignee: Novartis AG. Priority date: 14/10/2019. Publication date: 08/11/2022.
5. Carrasco K, Boufenzer A, Jolly L, Le Cordier H, Wang G, Heck AJ, Cerwenka A, Vinolo E, Nazabal A, Kriznik A et al.. (2019) TREM-1 multimerization is essential for its activation on monocytes and neutrophils. Cell Mol Immunol, 16 (5): 460-472. [PMID:29568119]
6. Cho S, Gaamouch FE, Upadhyay S, Nada H, Kuncewicz K, Gabr MT. (2025) As48, a First-in-Class Dual-Function TREM2 Modulator: Receptor Activation and Shedding Inhibition. bioRxiv,. [PMID:40909719]
7. Cho S, Kaur B, Lam K, Gaamouch FE, Kuncewicz K, Doering NP, Wolber G, Gabr MT. (2025) Structure-Based Virtual Screening Identifies TREM2-Targeted Small Molecules that Enhance Microglial Phagocytosis. bioRxiv,. [PMID:40909477]
8. Cho S, Szalai TV, El Gaamouch F, Bajusz D, Keserű GM, Gabr M. (2025) AI-Assisted Discovery and Optimization of Small Molecule TREM2 Agonists with Functional Microglial Activity. bioRxiv,. [PMID:41000669]
9. Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, Joyce PF, Szymkowski DE, Desjarlais JR. (2008) Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol, 45 (15): 3926-33. [PMID:18691763]
10. Curtis D, Joseph S, Alzheimer’s Disease Neuroimaging Initiative. (2025) Analysis of whole genome sequence data shows association of Alzheimer's disease with rare coding variants in ABCA7, PSEN1, SORL1 and TREM2. J Neurogenet, 39 (4): 95-104. [PMID:40990081]
11. Cuvier V, Lorch U, Witte S, Olivier A, Gibot S, Delor I, Garaud JJ, Derive M, Salcedo-Magguilli M. (2018) A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition. Br J Clin Pharmacol, 84 (10): 2270-2279. [PMID:29885068]
12. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. (2021) Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med, 384 (22): 2092-2101. [PMID:33835769]
13. Ji KY, Kim SM, Yee SM, Kim MJ, Ban YJ, Kim EM, Lee EH, Choi HR, Yun H, Lee CW et al.. (2021) Cyclophilin A is an endogenous ligand for the triggering receptor expressed on myeloid cells-2 (TREM2). FASEB J, 35 (4): e21479. [PMID:33710680]
14. Joller N, Anderson AC, Kuchroo VK. (2024) LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity, 57 (2): 206-222. [PMID:38354701]
15. Long H, Simmons A, Mayorga A, Burgess B, Nguyen T, Budda B, Rychkova A, Rhinn H, Tassi I, Ward M et al.. (2024) Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease. Alzheimers Res Ther, 16 (1): 235. [PMID:39444037]
16. Mjalli A, Andrews R, Shen J, Rothlein R. (2005) Rage antagonists as agents to reverse amyloidosis and diseases associated therewith. Patent number: US20050026811 A1. Assignee: Mjalli A, Andrews R, Shen J, Rothlein R. Priority date: 20/05/2003. Publication date: 03/02/2005.
17. Mummery CJ, Mayorga AJ, Simmons A, Chow TW, Burgess B, Nguyen T, Gao J, Budda B, Park LQ, Gupta R et al.. (2026) The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial. Nat Med, 32 (5): 1708-1716. [PMID:41787076]
18. Nada H, El Gaamouch F, Cho S, Kuncewicz K, Calvo-Barreiro L, Gabr MT. (2025) TREM2 Activation by First-in-Class Direct Small Molecule Agonists: DEL Screening, Optimization, Biophysical Validation, and Functional Characterization. bioRxiv, Preprint. [PMID:40501642]
19. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem, 267 (21): 14998-5004. [PMID:1378843]
20. Read CB, Kuijper JL, Hjorth SA, Heipel MD, Tang X, Fleetwood AJ, Dantzler JL, Grell SN, Kastrup J, Wang C et al.. (2015) Cutting Edge: identification of neutrophil PGLYRP1 as a ligand for TREM-1. J Immunol, 194 (4): 1417-21. [PMID:25595774]
21. Saeb D, Lietzke EE, Fuchs DI, Aldrich EC, Bruce KD, Sprenger KG. (2025) The flexible stalk domain of sTREM2 modulates its interactions with brain-based phospholipids. Elife, 13. [PMID:40928206]
22. Saito S, Ihara M. (2014) New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci, 6: 290. [PMID:25368578]
23. Schlepckow K, Morenas-Rodríguez E, Hong S, Haass C. (2023) Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease. Lancet Neurol, 22 (11): 1048-1060. [PMID:37863592]
24. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M, Stern D. (1996) RAGE: a novel cellular receptor for advanced glycation end products. Diabetes, 45 Suppl 3: S77-80. [PMID:8674899]
25. Sharma C, Mazumder A. (2025) From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease. Cent Nerv Syst Agents Med Chem, [Epub ahead of print]. [PMID:40993929]
26. Shen ZT, Sigalov AB. (2017) Rationally designed ligand-independent peptide inhibitors of TREM-1 ameliorate collagen-induced arthritis. J Cell Mol Med, 21 (10): 2524-2534. [PMID:28382703]
27. Siegler JE, Klein P, Yaghi S, Vigilante N, Abdalkader M, Coutinho JM, Abdul Khalek F, Nguyen TN. (2021) Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia. Stroke, 52 (9): 3045-3053. [PMID:34304601]
28. Sigalov AB. (2020) SCHOOL of nature: ligand-independent immunomodulatory peptides. Drug Discov Today, 25 (8): 1298-1306. [PMID:32405248]
29. Sigalov AB. (2025) TREM-1 inhibitor specificity and timing of treatment initiation can impact its therapeutic efficacy in cancer and inflammatory disease. Front Oncol, 15: 1689771. [PMID:41404075]
30. Smith CW, Montague SJ, Kardeby C, Di Y, Lowe GC, Lester WA, Watson SP, Nicolson PLR. (2021) Antiplatelet drugs block platelet activation by VITT patient serum. Blood, 138 (25): 2733-2740. [PMID:34375398]
31. Tsui JSM, Au DM, Uhm H, Wong WW, Lo RMN, Jiang Y, Ip FCF, Mok KY, Wong HY, Kwok TCY et al.. (2025) The TREM2 H157Y variant is associated with more severe neurodegeneration in Alzheimer's disease and altered immune-related processes. Alzheimers Dement, 21 (9): e70586. [PMID:40960087]
32. Xu X, Cai L, Dang X, Han J, Kou Y, Rong C, Kou J. (2026) Inhibition of TREM1 attenuates myocardial ischemia-reperfusion injury-induced cardiomyocyte pyroptosis by suppressing the activation of the NF-κB signaling pathway. PLoS One, 21 (1): e0340382. [PMID:41511954]
33. Yan SD, Stern D, Schmidt AM. (1997) What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose. Eur J Clin Invest, 27 (3): 179-81. [PMID:9088851]
34. Yang H, Kim D, Yang Y, Bagyinszky E, An SSA. (2025) TREM2 in Neurodegenerative Disorders: Mutation Spectrum, Pathophysiology, and Therapeutic Targeting. Int J Mol Sci, 26 (15). [PMID:40806186]
35. Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. (2016) TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron, 91 (2): 328-40. [PMID:27477018]
36. Yuan S, El Gaamouch F, Cho S, Kuncewicz K, Nada H, Gabr MT. (2025) Discovery of a Small Molecule TREM2 Agonist with Improved In Vitro Pharmacokinetic Profile and Validated Target Engagement. ACS Med Chem Lett, 16 (8): 1634-1640. [PMID:40832531]
37. Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Piña-Crespo JC, Zhang M et al.. (2018) TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function. Neuron, 97 (5): 1023-1031.e7. [PMID:29518356]
Database page citation:
Immunoglobulin like domain containing proteins. Accessed on 17/11/2026. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=984.
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Gibb AJ, Kelly E, Mathie AA, Peach CJ, Veale EL, Cidlowski JA, Davenport AP, Fabbro D, Spedding M, Striessnig J, Armstrong JF, Buneman OP, Faccenda E, Harding SD, Southan C, Davies JA et al. (2025) The Concise Guide to PHARMACOLOGY 2025/26: Introduction and Other Protein Targets. Br J Pharmacol. 182: S1-S23.

